Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.

Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A3, A4, A5, A6, L, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: Lubricant additives useful as friction reducing additives are disclosed herein that have a structure according to general formula I, where M is metal such as Ag, Au, Zn or Cu, and R1, R2, and R3, are each a hydrogen, or an alkyl, a substituted alkyl, or an aryl group.

Abstract: The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.

Abstract: Provided are novel dinuclear indium catalysts of formula (A) that are capable of living and immortal ring opening polymerization and copolymerization of cyclic ester monomers for the preparation of biodegradable polymers and copolymers, in particular polyesters. Also disclosed are polymerization methods and polymer products. These dinuclear indium catalysts allow less costly, highly reactive living polymerization of cyclic ester monomers with possible high turn over rates and/or substantial stereo-chemical and microstructure control.

Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

Abstract: Mono-substituted TSA precursor Si-containing film forming compositions are disclosed. The precursors have the formula: (SiH3)2N—SiH2—X, wherein X is selected from a halogen atom; an isocyanato group; an amino group; an N-containing C4-C10 saturated or unsaturated heterocycle; or an alkoxy group. Methods for forming the Si-containing film using the disclosed mono-substituted TSA precursor are also disclosed.

Abstract: Novel branched oligoarylsilanes of general formula (I) A method of preparation of branched oligoarylsilanes is that a compound of general formula (III) Y-Qk-SiArn—R)3??(III), where Y stands for a residue of boronic acid or its ester or Br or I, reacts under Suzuki conditions with a reagent of general formula (IV) A-Xm-A??(IV), where A stands for: Br or I, provided that Y stands for a residue of boronic acid or its ester; or a residue of boronic acid or its ester, provided that Y stands for Br or I. A technical result is preparation of novel compounds, featured by a high luminescence efficiency, efficient intramolecular energy transfer from some molecular fragments to others, and an increased thermal stability.

Abstract: The present invention is related to a method for the synthesis of ethane-1-hydroxy-1,1-diphosphonic acid or its salt which includes the steps of reacting tetraphosphorus hexaoxide and acetic acid under controlled reaction conditions; hydrolyzing the formed ethane-1-hydroxy-1,1-diphosphonic acid condensates to form ethane-1-hydroxy-1,1-diphosphonic acid; further processing the ethane-1-hydroxy-1,1-diphosphonic acid solution. The process according to the method of the present invention is highly controllable and further is characterized by a high selectivity.

Abstract: The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds.

Abstract: The present invention relates to a process for obtaining materials with Metal Organic atomic structure and called MOF (MOF: Metal Organic Framework) type MIL-101 (Cr) and MIL-101-Cr-MX+ (MIL: Material from Institute Lavoisier), where MX+ can be any metal cation, such as Mg2+, Al3+ or Ti4+, using for its synthesis metal epoxides and alkoxides, avoiding the use of hydrofluoric acid (HF) or bases as synthesis controlling agents. The process of the present invention for the preparation of materials MOF MIL-101 (Cr) and MOF MIL-101-Cr-MX+ where MX+ can be any metal cation, such as Mg2+, Al3+ or Ti4+, consisting of: a) Synthesizing MOF MIL-101 (Cr) with epoxides, or Synthesizing MOF MIL-101-Cr-MX+ with metal alkoxides; and b) Purifying the synthesized MOF. in order to obtain 100% pure materials, with a controlled mesoporosity associated with a hysteresis P/P0 from 0.7 to 0.99, BET surface area from 2,500 to 3,500 m2/g, pore volume from 1.1 to 2.2 cm3/g, and pore diameter from 15 to 55 nm.

Abstract: A palladium(II) complex of formula (1) or a palladium(II) complex of formula (3). Also, processes for the preparation of the complexes, and their use in carbon-carbon and carbon-heteroatom coupling reactions.

Abstract: The present invention is directed to a novel complex synthesized from a Salen-type ligand. The novel complex contains a quaternary ammonium salt. The present invention is also directed to a preparation method of a copolymer of carbon dioxide and epoxide using the complex synthesized from a Salen-type ligand as a catalyst.

Abstract: One example embodiment includes inserting a chemical reagent into a process stream that contains one or more lignins to form one or more modified lignins. The formed one or more modified lignins are different than the one or more lignins in the process stream. The one or more modified lignins can be formed in the process stream before a precipitation stage and then separated from the process stream. Also, contaminates can be removed from the separated one or more modified lignins and the one or more modified lignins can be pressed and dried.

Abstract: The method is for separation of lignin from original black liquor (BLIN) that has a first precipitation phase (PR1/PR2) for precipitation of lignin by a first acidification using acidifier, CO2, at alkaline conditions, then separating a lignin cake with subsequent suspension of the lignin cake in a strong acid in order to leach out metals from the lignin followed by dewatering and obtaining a clean lignin product LP. Lignin germ particles (LG) are added to the original black liquor in the first precipitation stage, preferably between two phases in said precipitation stage, in order to increase lignin particle growth on such lignin germ particles instead of spontaneous nucleation of lignin particles in said original black liquor. This results in improved filterability in subsequent dewatering and lignin cake formation and hence an increased lignin yield.

Abstract: The invention concerns compounds of the formula (I) wherein: Y1 and Y2 are independently a monosaccharide or disaccharide; X1 and X2 are independently —(R9—O)m—, —(R10)p—, —O—(R11—O)q—, —R16—O—R17—O— or a covalent bond; Q1 and Q2 are independently a nitrogen-containing heterocycle moiety; Z1 and Z2 are independently —(O—R7)—, —(O—C(?O)—R8)a-, —O—C(?O)—R12—C(=0)-R13—, —O—C(?O)—R14—C(?O)—R15 or a covalent bond; R7-R17 are each independently C1-C6 alkyl; R1-R6 are each independently a linear or branched alkyl group; b, c, d, e, f, and g are 0 or 1, provided b+c+d equals at least 2 and e+f+g equals at least 2; and a, m, p, and q are each an integer from 1-6.

Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

Abstract: The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.

Abstract: The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment and/or prevention or amelioration of neurodegenerative diseases related to neuronal apoptosis or neuronal injury, or conditions related to or resulting from apoptosis, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis (ALS), retinal degeneration and detachment, peripheral neuropathy caused by genetic abnormalities, diabetes, polio, herpes, AIDS and chemotherapy, brain trauma, or ischemia and stroke. The active compounds are represented by Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, B, X, Y and Z are defined in the description of the invention. The present invention also includes compositions which comprise one or more of the compounds of Formula (I).

Abstract: The present invention relates to processes for preparing compounds of formula I: or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).

Abstract: A replication inhibitor, which is an agent for inhibiting replication of a geminivirus, and comprises a zinc finger protein that can specifically bind to at least full length of stem loop region DNA of the geminivirus, or a part thereof, and can inhibit formation of a stem loop structure.

Abstract: A protein nanofiber comprised of self-assembling pentamers, and a method for producing the protein nanofiber, in which the protein upon which the nanofiber is based is a specific form of COMP. The proteins self-assemble via electrostatic interactions to form fibers that extend longitudinally.

Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.

Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

Abstract: The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.

Abstract: Disclosed are immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.

Abstract: The present invention relates to a polypeptide (repebody) selectively bound to an immunoglobulin G, a polynucleotide which encodes the repebody, a vector containing the polynucleotide, a recombinant microorganism in which the polynucleotide is introduced, a method for producing the repebody using the recombinant microorganism, and a method for immobilizing or purifying an immunoglobulin G using the repebody. The repebody according to the present invention is useful as utilized for immobilization of an immunoglobulin G, purification of an immunoglobulin G, and production of an immunosensor, since the repebody selectively bound to an immunoglobulin G.

Abstract: Compositions and methods are described which use RAV proteins and genes that encode such proteins to regulate RNA silencing in plant cells. Novel ntRAV proteins and genes are also described.

Abstract: A method for treating osteoarthritis in a subject includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.

Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterization using lysenin.

Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: 3), FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7), and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and moss or any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.

Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Abstract: R-spondin variants comprising a ZNRF3 binding region of a first R-spondin and an LGR4 binding region of a second R-spondin are disclosed. Cell culture media and compositions containing the R-spondin variants, as well as methods of their use, are also disclosed.

Abstract: Arrangements and methods are provided for obtaining information associated with an anatomical sample. For example, at least one first electro-magnetic radiation can be provided to the anatomical sample so as to generate at least one acoustic wave in the anatomical sample. At least one second electro-magnetic radiation can be produced based on the acoustic wave. At least one portion of at least one second electro-magnetic radiation can be provided so as to determine information associated with at least one portion of the anatomical sample. In addition, the information based on data associated with the second electro-magnetic radiation can be analyzed. The first electro-magnetic radiation may include at least one first magnitude and at least one first frequency. The second electro-magnetic radiation can include at least one second magnitude and at least one second frequency.

Abstract: The present invention demonstrated that soluble fibrin binds to both Mac-1 and ICAM-1-expressing cells and inhibited adherence of these cells and immune cytotoxicity, thus inducing immune suppression in cancer. Additionally, the present invention also demonstrated that soluble fibrin enhanced metastasis in an in vivo model. Furthermore, the present invention demonstrated the utility of specific peptides that block binding of soluble fibrin to these cells as therapeutic agents in cancer progression and metastasis. It is further contemplated that these peptides can also be used to treat other diseases such as cardiovascular disease, arthritis and in many inflammatory responses where there is increased levels of soluble fibrin.

Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.

Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.

Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).

Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.

Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.

Abstract: The present invention relates to a novel antibody specifically binding to human and mouse L1CAM, and more particularly, to an antibody binding to both human and mouse L1CAM with high affinity, which is prepared by modifying a sequence of an L1 cell adhesion molecule (L1CAM)-specific antibody comprising a heavy-chain variable region of SEQ ID NO. 1 and a light-chain variable region of SEQ ID NO. 5, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide, a transformant introduced with the vector, a pharmaceutical composition for preventing or treating cancer comprising the antibody, a method for treating cancer using the antibody, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for providing information for cancer diagnosis using the antibody, and an antibody-drug conjugate prepared by conjugating a drug to the antibody.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.

Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.

Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.

Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.

Abstract: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.

Abstract: The invention provides HER2-binding proteins and VEGF-A-binding proteins having a reduced tendency to aggregate. Compositions and methods of use are also provided.